The Claim
Decision curve analysis shows that using plasma p-tau217 as a pre-screening tool provides greater net clinical benefit than ordering amyloid-PET for all patients across a range of clinically relevant risk thresholds.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Using a blood test for p-tau217 to screen patients for Alzheimer's disease results in better clinical outcomes than ordering amyloid-PET scans for everyone, when evaluated across multiple risk thresholds.
See the scientific wording
Decision curve analysis demonstrates that using plasma p-tau217 as a pre-screening tool provides greater net clinical benefit than ordering amyloid-PET for all patients across a range of clinically relevant risk thresholds.
When amyloid builds up in the brain, it causes a specific protein to leak into the blood at measurable levels. This protein in the blood tells doctors which people have brain amyloid and which do not, so only those with the protein need a costly brain scan.
What the research says
1 studyThis blood test can safely identify who doesn't need a costly brain scan, so doctors can avoid scanning everyone — saving money and resources without missing people who really need treatment.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.